罗格列酮治疗多囊卵巢综合征胰岛素抵抗临床研究

Clinical study of rosiglitazone treats the patients with polycystic ovary syndrome associated with insulin resistance

目的研究罗格列酮对多囊卵巢综合征(PCOS)患者高胰岛素血症的疗效,观察患者治疗前后生殖激素的变化以及有排卵月经的恢复情况。方法选择诊断为多囊卵巢综合征及空腹血胰岛素≥15.6uIU/ml的患者30例,每天早餐前口服罗格列酮4mg,共12周,比较治疗前后体重指数、腰臀围比、胰岛素水平、血糖、胰岛素抵抗指数、生殖激素水平和排卵率的变化。结果治疗12周后,基础胰岛素、空腹血糖、餐后2小时血糖、胰岛素抵抗指数、睾酮、黄体生成素、黄体生成素/卵泡刺激素比值显著降低,性激素结合球蛋白显著增高。结论罗格列酮可增强胰岛素敏感性,纠正糖代谢异常和高雄激素血症等内分泌紊乱,促进有排卵月经的恢复。

Objective To study the therapeutic effects of rosiglitazone on polycystic ovary syndrome and observed the changes of reproductive hormones and the resumption of ovulation and menses so as to explore its clinical significance in treatment of insulin resistance in PCOS patients. Methods 30 consecutive patients with the diagnosis of PCOS and basal insulin≥ 15.6uIU/ml took 4 mg of rosiglitazone every morning for a consecutive period of 12 weeks. The comparison of body mass index,ratio of waist to hip,insulin level,blood glucose level,insulin resistance index,reproductive hormones and ovulation rate was made. Results Basal insulin,fasting plasma glucose,blood glucose 2 hours after meal,insulin resistance index,testosterone and the ratio of LH/FSH decreased significantly while sex hormone binding protein increased significantly after treatment for 12 weeks. Conclusion Rosiglitazone has increased the tissue sensitivity to insulin,decreased the hyperand rogenism,modified sugar metabolism disturbance and improved the resumption of ovultion,suggesting some clinical implications.